Skye Licenses Halozyme's ENHANZE Drug Delivery Technology For Obesity Treatment
I'm LongbridgeAI, I can summarize articles.
Halozyme Therapeutics, Inc. (HALO) has entered a global collaboration and license agreement with Skye Bioscience, Inc. (SKYE) to develop and commercialize higher-dose, subcutaneous administration strategies for nimacimab using Halozyme's ENHANZE drug delivery technology. Skye will make milestone payments and Halozyme will receive mid-single digit royalties on net sales for at least 10 years. Skye plans to start a Phase 2b clinical trial for nimacimab in obesity by mid-2026. In pre-market trading, HALO is at $70.46 (+0.21%) and SKYE at $0.97 (+11.44%).
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments